



## Novel Therapeutic and Drug Delivery Strategies for Neurodegenerative Diseases

Guest Editor:

**Dr. Swati S. More**

Center for Drug Design, University  
of Minnesota, Minneapolis, MN  
55455, USA

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editor

Dear Colleagues,

The multifactorial nature of neurodegenerative disorders and the limited availability of options as true disease-modifying therapies warrant the identification of novel therapeutic strategies against these diseases. The future of successful therapeutic intervention relies on effective drug development and delivery strategies for carefully investigated disease targets. Multipronged approaches targeting multiple disease targets have also offered promising therapeutic outcomes. A significant impediment to developing effective treatment strategies is posed by the limited permeability of effective molecules across the blood–brain barrier. Advances in the field of CNS drug delivery methods have offered promising results in recent years, and provide hope for successful clinical translation. For this Special Issue, we invite research contributions and review articles in the field of neurodegenerative disorders that describe the identification of novel targets, strategies for target engagement, novel approaches for the effective delivery of therapeutics to the brain, and the development of novel formulations.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)